News for 'Serum Institute of India'

Covovax as Covid booster jab to be available on CoWIN soon

Covovax as Covid booster jab to be available on CoWIN soon

Rediff.com10 Apr 2023

Covovax is likely to be available on the portal in a few days at a price of Rs 225 per dose plus applicable GST.

HC finds posts against Serum Inst, Poonawala defamatory, orders it deleted

HC finds posts against Serum Inst, Poonawala defamatory, orders it deleted

Rediff.com6 Jun 2023

The Bombay high court on Monday said content posted by two individuals and their organisations against vaccine manufacturing major Serum Institute of India (SII) was "prima facie defamatory" and directed them to delete it.

'None of the existing vaccines can prevent emerging variants of Omicron'

'None of the existing vaccines can prevent emerging variants of Omicron'

Rediff.com25 Jan 2023

'We seem to be in a situation where we can do little, and nothing needs to be done anyway.'

DCGI orders Serum to suspend recruitment for COVID-19 vaccine trials

DCGI orders Serum to suspend recruitment for COVID-19 vaccine trials

Rediff.com11 Sep 2020

The DCGI also directed Serum Institute of India to increase the safety monitoring of the subjects already vaccinated as part of the trial, and submit the plan and report.

COVID-19 vaccine: Why Poonawalla wrote to Biden

COVID-19 vaccine: Why Poonawalla wrote to Biden

Rediff.com17 Apr 2021

'The US has invoked the Defence Act and banned export of raw materials.' 'This is as good as banning vaccines.'

Serum banks on Rabivax for sales boom

Serum banks on Rabivax for sales boom

Rediff.com5 Nov 2004

Vaccine manufacturer Serum Institute of India on Friday said Rabivax, the country's first Human Diploid Cell rabies vaccine launched by the company recently, would trigger the company's market share in this segment to about 30 per cent from the curre

Covishield accounts for 88% of Covid jabs in India

Covishield accounts for 88% of Covid jabs in India

Rediff.com1 Jan 2022

Serum Institute has the capacity to make 250 million doses of Covishield monthly.

50 lakh Covishield doses meant for export to UK to be used in India

50 lakh Covishield doses meant for export to UK to be used in India

Rediff.com8 May 2021

50 lakh doses of 'Covishield' vaccine earmarked by the Serum Institute for export to the United Kingdom have now been made available for the inoculation of 18-44 age group in 21 states/UTs in India, amid a surge in COVID-19 cases, official sources said.

Look Who's Following Karan Johar's Footsteps!

Look Who's Following Karan Johar's Footsteps!

Rediff.com20 Nov 2024

Siddharth Roy Kapur's RKF aims to raise around $50 million by offering up to a 50 per cent stake in the company.

Serum cuts vaccine price for states to Rs 300/dose

Serum cuts vaccine price for states to Rs 300/dose

Rediff.com28 Apr 2021

SII's CEO Adar Poonawalla took to Twitter to announce the "philanthropic" gesture.

Probe to find whether Serum fire was mishap or sabotage: Uddhav

Probe to find whether Serum fire was mishap or sabotage: Uddhav

Rediff.com22 Jan 2021

Maharashtra Chief Minister Uddhav Thackeray on Friday said that whether the fire at the Serum Institute of India (SII) was an accident or sabotage will be known only after the probe gets over.

Serum to launch Covid vaccine for children in 6 months: Poonawalla

Serum to launch Covid vaccine for children in 6 months: Poonawalla

Rediff.com14 Dec 2021

Currently, Covishield and other COVID vaccines are approved for people above the age of 18 years.

'We have to ensure vaccines work against new variants'

'We have to ensure vaccines work against new variants'

Rediff.com11 Jan 2022

Adar Poonawalla says it took a five-minute chat with his father Cyrus before making the decision to manufacture Covishield. The bet paid off, and handsomely. Serum Institute now has the capacity to make 4 billion doses of Covishield annually.

What is Adar Poonawalla up to?

What is Adar Poonawalla up to?

Rediff.com4 May 2021

What the UK is getting out of the Serum Institute is what India is losing. And the responsibility of the Indian State ought to have been to dictate where Serum Institute's vaccine doses should go, argues Ambassador M K Bhadrakumar.

Scamsters dupe SII of over Rs 1cr posing as Adar Poonawala

Scamsters dupe SII of over Rs 1cr posing as Adar Poonawala

Rediff.com11 Sep 2022

An FIR was launched against some unidentified persons for cheating the SII for more than Rs 1 crore, said the officials on Sunday.

The REAL Story Of The 1 Billion Vaccines

The REAL Story Of The 1 Billion Vaccines

Rediff.com1 Nov 2021

We should be relieved that we got the doses but we must also know where they came from and who was and who was not responsible for this achievement, notes Aakar Patel.

Expert panel bats for Covovax as Covid booster jab for adults

Expert panel bats for Covovax as Covid booster jab for adults

Rediff.com12 Jan 2023

It has been approved by the European Medicines Agency for conditional marketing authorisation.

Ambanis Own 10% of India's Wealth

Ambanis Own 10% of India's Wealth

Rediff.com9 Aug 2024

The Adani family, led by Chairman Gautam Adani, is the most valued first-generation family business at Rs 15.44 trillion.

Govt places second purchase order for 1 crore doses of Covishield

Govt places second purchase order for 1 crore doses of Covishield

Rediff.com4 Feb 2021

The Centre on Wednesday placed a second purchase order with the Serum Institute of India for the supply of one crore doses of Oxford-AstraZeneca COVID-19 vaccine 'Covishield', each costing Rs 210, including GST, sources said.

Maha gets 9.83 lakh vaccine doses against 17.5 lakh: Tope

Maha gets 9.83 lakh vaccine doses against 17.5 lakh: Tope

Rediff.com13 Jan 2021

Tope also informed that the Centre has asked the state to reduce the number of inoculation centers from 511 to 350, saying the government should focus on other emergencies also.

Dom's Take: India, here comes the vaccine!

Dom's Take: India, here comes the vaccine!

Rediff.com15 Jan 2021

Dominic Xavier salutes every single person involved in making this miracle possible.

Bharat Biotech seeks emergency nod for use of Covaxin

Bharat Biotech seeks emergency nod for use of Covaxin

Rediff.com8 Dec 2020

Covaxin is being indigenously developed by Bharat Biotech in collaboration with the Indian Council of Medical Research (ICMR).

Govt in talks with SII for Nipah antibody, may put imports on hold

Govt in talks with SII for Nipah antibody, may put imports on hold

Rediff.com21 Sep 2023

Given the recurring outbreaks in the last five years, the government is considering domestic manufacturing of monoclonal antibodies for treating Nipah virus infections and is in talks with Serum Institute of India, report Shine Jacob and Sohini Das.

Need Rs 3,000 cr to ramp up vaccine production: SII CEO

Need Rs 3,000 cr to ramp up vaccine production: SII CEO

Rediff.com6 Apr 2021

Serum Institute along with other vaccine producers have agreed with the government to sacrifice profits. There is no vaccine industry on the planet that has agreed to provide vaccines at such a subsidised price, he added.

Serum applies for EU Covishield nod through AstraZeneca

Serum applies for EU Covishield nod through AstraZeneca

Rediff.com30 Jun 2021

We have applied for marketing authorisation to the EMA through AstraZeneca. We will not sell the vaccine in the EU, said a company source.

Producing vaccines is not like making 2 minutes noodles

Producing vaccines is not like making 2 minutes noodles

Rediff.com27 May 2021

'Even if Serum Institute and Bharat Biotech were successful in ramping up production overnight, what happens to the capacity after the demand from India is met?' asks Sanjeev Nayyar.

New-Gen COVID Jabs Coming Soon...

New-Gen COVID Jabs Coming Soon...

Rediff.com28 May 2024

India currently does not have any XBB 1.5 variant-based vaccines available.

'Please be patient': Adar Poonawalla to nations waiting for Covishield

'Please be patient': Adar Poonawalla to nations waiting for Covishield

Rediff.com21 Feb 2021

Apart from making efforts to meet the requirements of India, the company is also trying its best to balance the needs of the rest of the world, he added.

AstraZeneca admits in court: Covishield causes TTS

AstraZeneca admits in court: Covishield causes TTS

Rediff.com30 Apr 2024

United Kingdom-headquartered pharmaceutical giant AstraZeneca (AZ) has admitted that in 'very rare cases' its Covid vaccine can cause a blood clot related side effect but the causal link is unknown, according to court papers being quoted in the UK media.

Covid vaccine to cost Rs 290 to govt; Rs 585 in pvt mkt: Serum

Covid vaccine to cost Rs 290 to govt; Rs 585 in pvt mkt: Serum

Rediff.com4 Jan 2021

Serum Institute of India, the world's largest vaccine manufacturer, has a licence to produce the shot and has already manufactured close to 50 million doses.

India's First Dengue Vaccine Likely To Be Ready By 2026

India's First Dengue Vaccine Likely To Be Ready By 2026

Rediff.com30 Jul 2024

Dengue has become a major public health concern in India with 289,235 cases reported last year. This year there were 19,447 cases of dengue which resulted in 19 deaths till April 2024.

Amid Covid surge, the reality: Fewer vaccination centres

Amid Covid surge, the reality: Fewer vaccination centres

Rediff.com10 Apr 2023

Serum Institute of India (SII) and Bharat Biotech have also stopped producing the Covishield and Covaxin vaccines respectively.

Who shouldn't take jab? Vaccine makers issue fact sheet

Who shouldn't take jab? Vaccine makers issue fact sheet

Rediff.com19 Jan 2021

The fact sheet also asked people to inform the vaccinator or a supervising official about their medical condition before taking the vaccine.

His wealth grew the fastest in India during pandemic

His wealth grew the fastest in India during pandemic

Rediff.com23 Jun 2020

Pune-based entrepreneur's unlisted company is already the largest vaccine manufacturer in the world and the networth has been helped by vaccine distribution and manufacturing potential of his business, it added. Recentrly, Serum struck an agreement with AstraZeneca to manufacture 1 billion doses of coronavirus vaccine being developed by Oxford University.

Govt orders 66 cr Covishield doses from SII by Dec

Govt orders 66 cr Covishield doses from SII by Dec

Rediff.com9 Sep 2021

The development comes after Prakash Kumar Singh, the Director, Government and Regulatory Affairs at SII, informed the Union health ministry that the firm would be able to supply 20.29 crore doses of Covishied in the month of September.

Reliance, Tata on TIME's list of world's most influential companies

Reliance, Tata on TIME's list of world's most influential companies

Rediff.com30 May 2024

Billionaire Mukesh Ambani's Reliance Industries and Tata Group have made it to the prestigious TIME's list of 100 World's Most Influential Companies of 2024. TIME called Reliance 'India's Juggernaut'. This is the second time that Reliance has found its way into the TIME list. Jio Platforms, the firm that holds digital properties of the conglomerate, was included in the inaugural TIME 100 Most Influential Companies List of 2021. Serum Institute is the other Indian company on the list.

Covishield booster dose to be priced at Rs 600: Serum

Covishield booster dose to be priced at Rs 600: Serum

Rediff.com8 Apr 2022

The Union Health Ministry on Friday announced that those above the age of 18 years who have completed nine months after the administration of the second dose will be eligible for the precaution dose.

'Bharat Serums and Vaccines portfolio can touch Rs 5K cr in 3-4 years'

'Bharat Serums and Vaccines portfolio can touch Rs 5K cr in 3-4 years'

Rediff.com9 Aug 2024

'Mankind's experience, sharpness, and execution will make it happen. We are not going for short-term gains.'

SII to raise monthly production to 10 cr doses by Aug, Bharat Biotech promises 7.8 cr

SII to raise monthly production to 10 cr doses by Aug, Bharat Biotech promises 7.8 cr

Rediff.com12 May 2021

Several states and UTs including Delhi, Maharashtra, Karnataka and Telangana have decided to opt for global tenders for procurement of anti-coronavirus shots with the domestic supply falling short to meet the rising demand.

India approves Oxford's, Bharat Biotech's vaccines for emergency use

India approves Oxford's, Bharat Biotech's vaccines for emergency use

Rediff.com3 Jan 2021

The approval by the Drugs Controller General of India (DCGI) was given on the basis of recommendations submitted by a COVID-19 subject expert committee (SEC) of the Central Drugs Standard Control Organisation (CDSCO).